BACKGROUND: We aimed to clarify the impact of the donor source of allogeneic stem cell transplantation (allo-SCT) on Philadelphia chromosome-negative acute lymphoblastic leukemia [Ph(-) ALL] with focus on cord blood (CB). PATIENTS AND METHODS: We retrospectively analyzed data of 1726 patients who underwent myeloablative allo-SCT for adult Ph(-) ALL. The sources of the allo-SCT were related donors (RD; N = 684), unrelated donors (URD; N = 809), and CB (N = 233). RESULTS: Overall survival (OS) in patients after CB allo-SCT in first complete remission (CR1) was comparable with that after RD or URD allo-SCT (RD: 65%, URD: 64% and CB: 57% at 4 years, P = 0.11). CB was not a significant risk factor for relapse or non-relapse mortality as well as for OS in multivariate analyses. Similarly, the donor source was not a significant risk factor for OS in subsequent CR or non-CR (RD: 47%, URD: 39% and CB: 48% in subsequent CR, P = 0.33; RD: 15%, URD: 21% and CB: 18% in non-CR, P = 0.20 at 4 years). CONCLUSION: Allo-SCT using CB led to OS similar to those of RD or URD in any disease status. To avoid missing the appropriate timing, CB is a favorable alternative source for adult Ph(-) ALL patients without a suitable RD or URD.
BACKGROUND: We aimed to clarify the impact of the donor source of allogeneic stem cell transplantation (allo-SCT) on Philadelphia chromosome-negative acute lymphoblastic leukemia [Ph(-) ALL] with focus on cord blood (CB). PATIENTS AND METHODS: We retrospectively analyzed data of 1726 patients who underwent myeloablative allo-SCT for adult Ph(-) ALL. The sources of the allo-SCT were related donors (RD; N = 684), unrelated donors (URD; N = 809), and CB (N = 233). RESULTS: Overall survival (OS) in patients after CB allo-SCT in first complete remission (CR1) was comparable with that after RD or URD allo-SCT (RD: 65%, URD: 64% and CB: 57% at 4 years, P = 0.11). CB was not a significant risk factor for relapse or non-relapse mortality as well as for OS in multivariate analyses. Similarly, the donor source was not a significant risk factor for OS in subsequent CR or non-CR (RD: 47%, URD: 39% and CB: 48% in subsequent CR, P = 0.33; RD: 15%, URD: 21% and CB: 18% in non-CR, P = 0.20 at 4 years). CONCLUSION: Allo-SCT using CB led to OS similar to those of RD or URD in any disease status. To avoid missing the appropriate timing, CB is a favorable alternative source for adult Ph(-) ALL patients without a suitable RD or URD.
Authors: S Nishiwaki; K Imai; S Mizuta; H Kanamori; K Ohashi; T Fukuda; Y Onishi; S Takahashi; N Uchida; T Eto; H Nakamae; T Yujiri; S Mori; T Nagamura-Inoue; R Suzuki; Y Atsuta; J Tanaka Journal: Bone Marrow Transplant Date: 2015-09-21 Impact factor: 5.483
Authors: David I Marks; Kwang Ahn Woo; Xiaobo Zhong; Frederick R Appelbaum; Veronika Bachanova; Juliet N Barker; Claudio G Brunstein; John Gibson; Partow Kebriaei; Hillard M Lazarus; Richard Olsson; Miguel-Angel Perales; Joseph Pidala; Bipin Savani; Vanderson Rocha; Mary Eapen Journal: Haematologica Date: 2013-09-20 Impact factor: 9.941
Authors: Veronika Bachanova; Wael Saber; Ashley Rosko; Hai-Lin Wang; Marcos de Lima; Brenda Sandmaier; H Jean Khoury; Andrew Artz; Johnathan Brammer; Christopher Bredeson; Sherif Farag; Mohamed Kharfan-Dabaja; Hillard M Lazarus; David I Marks; Rodrigo Martino Bufarull; Joseph McGuirk; Mohamed Mohty; Taiga Nishihori; Ian Nivison-Smith; Armin Rashidi; Olle Ringden; Matthew Seftel; Daniel Weisdorf Journal: Am J Hematol Date: 2016-11-12 Impact factor: 10.047